Pharma stocks has outperformed the MSCI India Index by 40% in the last three years. However, several looming challenges threaten the momentum in many of the stocks. Scroll down for three names that the analysts continue to be bullish on.
Brokerage firm JPMorgan has adopted a more selective and cautious stance on India’s healthcare sector, downgrading the pharmaceutical space to ‘underweight’, citing concerns over earnings volatility, tariff risks, and a fading growth profile.
Continue Reading with
Continue Reading with
CNBC-TV18 Access Membership
Priority Access and Networking: CNBC-TV18’s flagship events
Interaction with CNBC-TV18’s journalists
Webinars & LIVE Q&As with India Inc. Leaders
Exclusive CNBC-TV18 studio & newsroom tours
Premium business insights, expert opinions & analysis
Curated lifestyle privileges & offers
